British EnsiliTech Secures €5.2M Seed for Cold-Chain Biopharma

Bristol-based EnsiliTech secured €5.2 million in Seed funding. Eos Advisory led the round, aiming to transform global biopharma transport. This EnsiliTech funding supports the company's mission to eliminate cold-chain reliance for life-saving medicines.

Founded in 2022, EnsiliTech developed patented Ensilication technology. This innovation stabilizes biopharmaceuticals, including vaccines and antibodies, at temperatures up to 50°C. Furthermore, it encapsulates delicate biological materials within a protective silica layer, preserving integrity during transit. Consequently, the silica shell disintegrates upon use, releasing the active medicine.

Revolutionizing Pharmaceutical Logistics

The global pharmaceutical industry faces an estimated €30 billion in annual losses from cold-chain failures. Traditional systems require constant refrigeration, leading to significant waste, especially in developing regions. EnsiliTech's solution therefore reduces supply-chain costs, minimizes drug waste, and lowers the environmental impact of distribution. This biotechnology innovation addresses a critical need.

The fresh capital will accelerate technology adoption. EnsiliTech plans team and infrastructure expansion, plus validation studies for manufacturing integration.

EnsiliTech previously raised €1.3 million in 2023. The startup also features a predominantly female-led R&D and executive team. HERmesa, an investor group supporting women-led companies, participated in this startup investment round. Competitors like Catalent, Lonza, and UPS Healthcare also explore advanced drug delivery or logistics methods.

Calculus Capital, Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol (AIB), Penn Park Capital, and chANGELS joined the EnsiliTech funding round. Several individual angel investors also contributed. This broad backing underscores the potential for global health impact in pharmaceutical logistics.